TP53 and cancer: Recent studies have demonstrated functional inactivation of MDM2 and CHIP E3 ligase activity by HSP90 inhibition, resulting in aberrant stabilization of mutant p53 [34], and SAHA inhibited cell growth in mutant p53 human cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-HSP90 chaperone axis [33].